Clinical pharmacological studies on centpropazine--a new antidepressant compound.
Article
in English
| IMSEAR
| ID: sea-20119
ABSTRACT
Single oral doses of 10 to 160 mg centpropazine, a new antidepressant (synthesized by CDRI, Lucknow, India) were administered to groups of 4-5 male volunteers, each dose being interspersed with placebo in a double blind, non-crossover study by random distribution. The drug was well tolerated. Drowsiness, heaviness, weakness and/or headache were reported only at doses of 120 mg and above. No adverse effect was noted in various laboratory tests, ECG or vital parameters. In a multiple dose study, volunteers received 40 or 80 mg centpropazine daily for 4 wk. Mild restlessness and insomnia were observed in some subjects receiving 80 mg dose. In this study also no effect was observed in various laboratory tests, ECG or vital parameters.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Piperazines
/
Aged
/
Humans
/
Male
/
Random Allocation
/
Double-Blind Method
/
Adolescent
/
Adult
/
Dose-Response Relationship, Drug
/
Drug Evaluation
Type of study:
Controlled clinical trial
Language:
English
Year:
1989
Type:
Article
Similar
MEDLINE
...
LILACS
LIS